AI also supports reverse vaccinology, where pathogen genomes are computationally analyzed to identify immunogenic regions ...

No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Nicotine vaping continues to outperform FDA-approved smoking cessation therapies in well-designed studies, including a new ...

Antibiotic resistance is one of the world's leading causes of death, claiming the lives of more people than HIV / AIDS or ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum antiviral drugs known as “nanoviricides”. These agents mimic cell surface ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed a compound that could work as a broad-spectrum drug targeting a range of coronaviruses. Their ...

disease. “Our study has provided the first evidence to prove PLpro is a powerful new drug target for COVID-19 treatments, while also showing its potential ability to treat the virus with unprecedented ...